Novartis strikes a $103M deal for bluebird's PRV — if it wins one
An FDA decision on bluebird bio’s third gene therapy isn’t expected until December, but Novartis has already locked up a potential priority review voucher that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
